Any current/future new fundraising through debt or equity?

The company currently has a net debt below INR 500 crores, considering uncalled rights issue money of INR 222 crores. Solara does not expect to be net cash positive by next year but anticipates reaching a strong or near net cash position by FY '27. There is no specific mention of immediate or planned new fundraising through debt or equity in the discussed call. The focus is on running the existing capex program internally approved, with a capex plan of about INR 100 crores primarily for the Vizag facility. Management emphasizes disciplined operations and internal cash generation to manage grow

Any current/future capex/capital investment/strategic investment?

Vizag Facility Capex: Approximately INR 100 crores planned as part of retrofitting and capacity expansion. Existing Gross Block at Vizag: Around INR 500 crores, with net block about INR 250 crores. Vizag refurbishment focuses on converting the mothballed plant into a multipurpose facility for HPAPI and polymers, targeting product diversification and growth. Capital investment aimed at ramping up operations to peak for 3 quarters in FY '26. No specific new capital expenditures mentioned besides the Vizag facility enhancement. Growth capex to be funded largely through internal accruals. Net debt

Future growth expectations in sales/revenue/volumes?

Solara expects calibrated growth in FY '25 with a focus on margin expansion and customer satisfaction. Q4 FY '25 revenue run rate is guided at around INR 400 crores, up from approximately INR 347 crores in Q2. The Vizag facility, after retrofitting, is expected to become operational from Q1 FY '26 and contribute significantly to growth with three full quarters of operation. The company targets revenue growth driven by existing portfolios rather than new DMFs, focusing on commercialization and cost improvements. CRAMS business is projected to grow rapidly over the next 2-3 years, moving towards

Future growth expectations in earnings/operating earnings/profits/EPS?

Solara aims calibrated growth focused on profitable expansion, with EBITDA expected within guided INR80-90 crores in Q4 FY25, trending ~20% EBITDA margin. H1 FY25 revenues reached ~45-47% of annual guidance; confident of meeting full-year revenue and margin outlooks. Vizag facility refurbishment to drive growth in FY26 with three full quarters of operation, expanding capacity in polymers and high-potency APIs. EBITDA growth driven by cost containment, governance, and targeted portfolio; opex reduced significantly and expected to stabilize near INR130-135 crores with Vizag ramp-up. Regulated ma

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the exact current or expected order book or pending orders in quantitative terms. Arun Kumar mentioned "We have seeded a lot of customers" in CRAMS, indicating growing business and a healthy pipeline. The company has a large portfolio of DMFs (around 70-75) focused on commercializing existing products rather than aggressively filing new ones. The Vizag facility retrofit is expected to contribute significantly starting Q1 FY'26, providing new revenue opportunities. Guidance suggests confidence in meeting revenue and EBITDA targets, indicating a stable

IN US

Sale is live|00:00:00left today

Solara Active Pharma Sciences LtdQ3 FY24Pharmaceuticals & Biotechnology

Solara Active Pharma Sciences Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹570Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Solara expects calibrated growth in FY '25 with a focus on margin expansion and customer satisfaction.
→Q4 FY '25 revenue run rate is guided at around INR 400 crores, up from approximately INR 347 crores in Q2.
→The Vizag facility, after retrofitting, is expected to become operational from Q1 FY '26 and contribute significantly to growth with three full quarters of operation.
→The company targets revenue growth driven by existing portfolios rather than new DMFs, focusing on commercialization and cost improvements.
→CRAMS business is projected to grow rapidly over the next 2-3 years, moving towards 10% of sales by FY '26.
→Regulated market sales are expected to remain around 76% or potentially increase, supporting stable pricing and margins.
→Overall, revenues are expected to rise with Vizag's full operation and ongoing business focus, but detailed FY '26 guidance is deferred until Q4.

Margin guidance

Category 3

→Solara aims calibrated growth focused on profitable expansion, with EBITDA expected within guided INR80-90 crores in Q4 FY25, trending ~20% EBITDA margin.
→H1 FY25 revenues reached ~45-47% of annual guidance; confident of meeting full-year revenue and margin outlooks.
→Vizag facility refurbishment to drive growth in FY26 with three full quarters of operation, expanding capacity in polymers and high-potency APIs.
→EBITDA growth driven by cost containment, governance, and targeted portfolio; opex reduced significantly and expected to stabilize near INR130-135 crores with Vizag ramp-up.
→Regulated market revenue share stable at ~76%, providing pricing stability and margin improvement.
→CRAMS business growing, currently sub-INR100 crores annualized, expected rapid growth over 2-3 years.
→Focus on optimizing existing DMFs and selective new filings (4-5 per year), prioritizing commercialization and cost efficiency.
→Net debt expected to reduce toward near net-cash position by FY27, supporting sustainable growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→The company currently has a net debt below INR 500 crores, considering uncalled rights issue money of INR 222 crores.
→Solara does not expect to be net cash positive by next year but anticipates reaching a strong or near net cash position by FY '27.
→There is no specific mention of immediate or planned new fundraising through debt or equity in the discussed call.
→The focus is on running the existing capex program internally approved, with a capex plan of about INR 100 crores primarily for the Vizag facility.
→Management emphasizes disciplined operations and internal cash generation to manage growth and debt reduction without highlighting new fundraising activities.

Order book

→The transcript does not explicitly mention the exact current or expected order book or pending orders in quantitative terms.
→Arun Kumar mentioned "We have seeded a lot of customers" in CRAMS, indicating growing business and a healthy pipeline.
→The company has a large portfolio of DMFs (around 70-75) focused on commercializing existing products rather than aggressively filing new ones.
→The Vizag facility retrofit is expected to contribute significantly starting Q1 FY'26, providing new revenue opportunities.
→Guidance suggests confidence in meeting revenue and EBITDA targets, indicating a stable and growing orderbook aligned with internal targets.
→Management emphasizes a calibrated growth strategy, focusing on profitable and sustainable orders rather than volume chase.

Capex plans

Yes

→Vizag Facility Capex: Approximately INR 100 crores planned as part of retrofitting and capacity expansion.
→Existing Gross Block at Vizag: Around INR 500 crores, with net block about INR 250 crores.
→Vizag refurbishment focuses on converting the mothballed plant into a multipurpose facility for HPAPI and polymers, targeting product diversification and growth.
→Capital investment aimed at ramping up operations to peak for 3 quarters in FY '26.
→No specific new capital expenditures mentioned besides the Vizag facility enhancement.
→Growth capex to be funded largely through internal accruals.
→Net debt expected to reduce gradually, with the company targeting to be near net cash positive by FY '27, not FY '26.
→Strategic focus on cost containment and capacity utilization rather than aggressive new investments currently.

How does Solara Active Pharma Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Solara Active Pharma Sciences Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Solara Active Pharma Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio